Hair loss discussion includes treatments like Minoxidil, Finasteride, and RU58841. Users share experiences and support, mentioning that many people face hair thinning.
New potential hair loss treatment uses molecules from hairy moles to stimulate follicle growth. Topical solution requires less frequent application, like Botox injections a few times per year.
The conversation is about a person considering participating in a study for Clascoterone, a topical cream for hair loss, and seeking advice on potential side effects. They have mild hair loss and are not currently using other treatments like finasteride.
FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.
The conversation is about a new acne treatment cream called Clascoterone Cream 1%, which is the first new mechanism of action for acne in nearly 40 years. One person joked about hoping their face will be as clean as their bald head after using the cream.
A humorous discussion about a newborn's hair loss, jokingly suggesting treatments like Minoxidil, finasteride, and various other hair loss remedies. Participants humorously debate extreme measures, including shaving or using a "nuclear stack" of treatments.
Pyrilutamide, a possible hair loss treatment, ceasing to be traded due to patent laws; and the hope that this indicates it may be a legitimate treatment.
A 20-year-old male with a high hairline seeks advice on potential hair loss, noting a family history that typically doesn't progress beyond Norwood 2. A user suggests it appears to be a mature hairline rather than hair loss and advises monitoring for changes.
PP405 cannot restore extracted hair follicles after a transplant as they are removed, not dormant. Combining verteporphin with wounding and PP405 is suggested but not confirmed effective.
The user underwent two FUT hair transplant surgeries with subpar results, leading to disappointment and continued use of Minoxidil, laser cap, dermaroll, and biotin. They advise thorough research before committing to hair transplants, especially for those with advanced hair loss.
The conversation is about people with advanced hair loss (Norwood 6 or 7) who have seen significant hair regrowth using treatments like finasteride, minoxidil, microneedling, and RU58841. Nine cases were collected to motivate others to try these treatments despite advanced hair loss.
A user shared progress pictures 1.5 months after a hair transplant of 3500 grafts, using oral finasteride, topical finasteride, minoxidil, and vitamins. They are concerned about potential shock loss and the thinning appearance.
South Korea's president is advocating for hereditary hair loss to be covered by national health insurance due to its impact on mental health and daily functioning. The discussion highlights the societal pressure in South Korea regarding appearance and the potential benefits of treating hair loss to improve mental health.
A 28-year-old underwent three hair transplants totaling 11,102 grafts at Eugenix, using finasteride and minoxidil to manage advanced hair loss. Despite limited density, the results are satisfactory, allowing the individual to feel presentable without a hat.
A 46-year-old man is using minoxidil, finasteride, and derma rolling for hair regrowth but is unsure of the results and considering a hair transplant. Many suggest he looks good bald and recommend continuing treatment or trying scalp micropigmentation.
Orient Bio is developing a PLGA formulated version of Cyclosporine A to stimulate hair growth without its immunosuppressant effects. Users discuss various treatments like Clascoterone, PP405, minoxidil, and tacrolimus, expressing hope for new developments and sharing personal experiences with these treatments.
Hair transplants have improved significantly from the old "plug" method, which left unnatural results. Modern techniques by skilled doctors can achieve natural-looking hairlines.
The conversation discusses hair loss concerns, specifically traction alopecia and hair loss from acne. It mentions that sleeping on one side is unlikely to cause traction alopecia.
Clascoterone's full trial results are expected by mid-July 2026, but skepticism exists about timely release. Clascoterone is available at 5% from some telehealth companies.
The conversation is about whether doctors are offering hair transplants using verteporfin. Dr. Bargouthi in Jordan and Dr. Bloxham in New York are currently conducting trials on it.
Carnosic acid in rosemary extract may enhance skin repair and promote hair follicle regeneration. It could be used alone or with verteporfin for scarless healing after dermal wounding.
Microneedling can aid hair regrowth but poses risks like permanent hair loss if not done properly. Combining it with minoxidil, finasteride, and tretinoin, while ensuring proper sterilization and technique, is crucial for safety and effectiveness.
Accepting baldness and the various ways people try to cope with it, such as shaving, using medications like minoxidil and finasteride, or getting a hair transplant. Participants discussed how true acceptance of hair loss involves confronting difficult emotions such as grief for one's former appearance and identity, as opposed to simply superficially hiding it with a shaved head.
A non-binary individual experienced hair loss after stopping hormone replacement therapy and is using oral Dutasteride, oral Minoxidil, and ketoconazole shampoo. They are hopeful for regrowth but may use wigs due to the high cost and uncertain effectiveness of additional treatments like mesotherapy and PRP.
A South Korean company, Therazyne, has developed a promising hair loss treatment using a WNT chain surrogate that binds to Frizzled 7, with human follicle testing expected soon. Current treatments like minoxidil and finasteride are not seen as cures, and while optimism exists for future solutions like PP405, approval processes are lengthy.
HairClone is offering a Dermal Papilla Cell Hair Multiplication procedure in Guatemala, raising questions about its effectiveness and regulatory reasons for the location. Users express skepticism and curiosity about the treatment's success and potential costs.